Emyria Raises $4M, Opens Second Clinic, and Reports 63% PTSD Recovery Rate
Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.
- Multi-year funding agreement with Medibank for Empax PTSD treatment
- Second Empax Clinic opened at Perth Clinic to expand treatment capacity
- Six-month follow-up shows 63% of patients no longer meet PTSD criteria
- Raised over $4 million via placement to support growth and patient access
- Focus on scaling reimbursed mental health programs nationally
A Landmark Funding Agreement
Emyria Limited has taken a significant step forward in mental health care by securing a multi-year funding agreement with Medibank, Australia’s largest private health insurer. This deal marks the first time a major insurer in Australia has agreed to reimburse a psychotherapy-led treatment for PTSD, specifically through Emyria’s Empax program at its Perth Clinic. The agreement is part of Medibank’s broader $50 million mental health investment initiative and aims to reduce financial barriers for patients with complex PTSD, making high-quality care more accessible.
Clinical Outcomes That Impress
Emyria’s recent six-month follow-up data on its initial PTSD cohort is compelling. Among eight treatment-resistant patients, 63% no longer met the diagnostic criteria for PTSD, with an average symptom severity reduction of 55.5%. Quality-of-life scores improved dramatically, with a 121.5% increase on the ReQoL-10 scale, and 63% of patients achieved scores comparable to the general population. These durable outcomes underscore the potential of Emyria’s psychiatrist-led, multidisciplinary Empax model to deliver lasting psychological recovery rather than short-term relief.
Expanding Capacity and Capability
To meet growing demand, Emyria opened a second Empax Centre within Perth Clinic, a licensed day hospital known for its patient-centred mental health care. This expansion allows the delivery of both PTSD and treatment-resistant depression programs in a payer-ready environment, positioning Emyria to scale its innovative treatments nationally. The company is actively engaging with other insurers and care providers to broaden reimbursement coverage and patient access.
Strengthening Financial Foundations
Supporting its growth ambitions, Emyria raised over $4 million through a two-tranche placement, attracting strong institutional and professional investor interest, including participation from company directors. The proceeds will fund the national rollout of reimbursed mental health programs, infrastructure development, and site expansion. At quarter-end, Emyria held $3.57 million in cash, with an additional $1.1 million expected pending shareholder approval.
Looking Ahead
Emyria’s executive leadership is focused on four strategic growth levers – expanding the Empax clinic footprint across Australia, broadening reimbursed indications beyond PTSD to include treatment-resistant depression, deepening insurer and public payer engagement, and enhancing real-world data infrastructure to improve personalised care and generate licensable intellectual property. These initiatives aim to address the escalating mental health crisis in Australia, where demand for effective, fundable treatments is urgent.
Bottom Line?
Emyria’s Medibank partnership and clinical progress set the stage for scaling innovative mental health treatments amid a national crisis.
Questions in the middle?
- How quickly will other major insurers follow Medibank in reimbursing Empax programs?
- Can Emyria sustain clinical outcomes as patient numbers grow beyond the initial cohort?
- What regulatory hurdles remain for broader adoption of MDMA-assisted therapies?
